Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,059.26 +40.87 (+0.81%) Dow
38,194.63 +291.34 (+0.77%) Nasdaq
15,817.35 +211.87 (+1.36%) Bitcoin USD
59,358.04 +1,358.95 (+2.34%) CMC Crypto 200
1,275.76 +5.02 (+0.39%)
BMY May 2024 59.000 call
| Previous close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0000 |
| Ask | 0.0200 |
| Strike | 59.00 |
| Expiry date | 2024-05-24 |
| Day's range | 0.0100 - 0.0100 |
| Contract range | N/A |
| Volume | |
| Open interest | 82 |
ZacksBiotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
GlobeNewswireEditas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer
Insider MonkeyBristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript April 25, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $-4.4, expectations were $-4.55. Bristol-Myers Squibb Company isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Bristol-Myers […]
